- Home
- GPN vs NBIX Comparison
GPN vs NBIX Comparison
Compare GPN & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPN | NBIX |
|---|---|---|
| Founded | 1967 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 14.4B |
| IPO Year | 2001 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GPN | NBIX |
|---|---|---|
| Price | $81.45 | $152.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 20 |
| Target Price | $103.20 | ★ $175.10 |
| AVG Volume (30 Days) | ★ 2.3M | 938.9K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 34.30 | 12.44 |
| EPS | ★ 7.12 | 4.19 |
| Revenue | ★ $10,076,185,000.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | $4.44 | $18.01 |
| P/E Ratio | ★ $11.53 | $36.45 |
| Revenue Growth | ★ 22.33 | 19.61 |
| 52 Week Low | $65.93 | $84.23 |
| 52 Week High | $117.56 | $160.18 |
Technical Indicators
Market Signals| Indicator | GPN | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 57.08 |
| Support Level | $77.16 | $151.09 |
| Resistance Level | $83.42 | $156.70 |
| Average True Range (ATR) | 2.02 | 4.19 |
| MACD | 0.92 | 0.12 |
| Stochastic Oscillator | 81.67 | 61.26 |
Price Performance
Historical ComparisonAbout GPN Global Payments Inc.
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.